Please assess the completion status of the following clinical trial:

Trial Title: A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have systemic signs and symptoms of inflammation as manifested NNS/CANDLE, SAVI, AGS~* Have been diagnosed with genetic diagnosis~* Men must agree to use a reliable method of birth control during the study~* Women not of child-bearing potential or nonbreastfeeding~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* NNS/CANDLE and SAVI patients who are ≥17.5 months of age~* AGS patients who are ≥6 months of age~* Are ≥ 5kg in body weight~Exclusion Criteria:~* Have received immunosuppressive biologic agent/monoclonal antibody/oral JAK inhibitor/OAT3 inhibitor and cannot discontinue prior to investigational product initiation. Note: A washout period is required to each drug.~* Have diagnosis of current active tuberculosis (TB) or, latent TB who did not receive appropriate treatment.~* Have had a serious infection within 12 weeks prior to screening.~* Have a history of lymphoproliferative disease~* Have any history of venous thromboembolic event (VTE) (deep vein thrombosis \[DVT\]/pulmonary embolism \[PE\]) prior to screening.~* Have had any major surgery within 8 weeks prior to screening.~* Have previously been enrolled in any other study investigating baricitinib.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Baricitinib (Type: EXPERIMENTAL): CANDLE:~Participants with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~SAVI:~Participants with STING-associated vasculopathy with onset during infancy (SAVI) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).~Aicardi-Goutières Syndrome (AGS):~Participants with Aicardi-Goutières Syndrome (AGS) received an optimized dosage of baricitinib that was determined throughout the dose-adjustment period administered as tablets or oral suspension based on participants weight and estimated glomerular filtration rate (eGFR).

Based on this trial design, predict the completion outcome and termination type (if applicable).